Mesa Laboratories (MLAB) Stock Analysis & AI Equity Report

Hardware, Equipment & Parts USD Explore free reports

Mesa Laboratories (MLAB) overview

Mesa Laboratories (MLAB) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 249m and operating profit of USD 18.5m; the year-end share price was 88.42 USD and market capitalisation was USD 489m. Mesa Laboratories is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Mesa Laboratories's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 186mFY 2026
Share price88.42 USDFY 2026 year end
RevenueUSD 249mFY 2026
Operating profitUSD 18.5mFY 2026
Net earningsUSD 6.7mFY 2026
Market capitalisationUSD 489mFY 2026 year end

About Mesa Laboratories

Mesa Laboratories designs and manufactures life sciences tools and quality control products for regulated pharmaceutical, healthcare, and medical device applications. Its offerings include biological, chemical, and cleaning indicators used to assess sterilization, disinfection, and cleaning processes, as well as sterility assurance testing and laboratory services. It also sells consumables and hardware and provides maintenance, calibration, and testing services.

Generate the Mesa Laboratories report

Mesa Laboratories is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Mesa Laboratories and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Mesa Laboratories

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.